After its recent appointment of Louis Drapeau to Bio-Rad's board of directors in late February, the American Stock Exchange has confirmed that Bio-Rad is in compliance with Amex listing rules
Drapeau will serve on the board's audit committee.
He replaces Philip Padou who passed away late last year.
Drapeau will stand for election to the board along with Bio-Rad's other directors at the company's annual meeting on April 24, 2007.
Drapeau currently serves as chief financial officer and senior vice president of finance at Nektar Therapeutics.
Previously, he has served in several executive positions at BioMarin Pharmaceutical, and audit partner and managing partner of northern California audit and business consulting at Arthur Andersen.
Drapeau currently serves on the board of directors of Inflazyme Pharmaceuticals where he is the chair of the board's audit committee.
